Trial Profile
A 4-Week, Phase-II, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multi-Centre Study to Assess the Efficacy and Tolerability/Safety of Inhaled AZD3199 Once Daily Compared to 9 μg Formoterol Bid and Placebo in Patients With Moderate to Severe COPD.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Dec 2016
Price :
$35
*
At a glance
- Drugs AZD 3199 (Primary) ; Formoterol
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms GLAD
- Sponsors AstraZeneca
- 28 Sep 2011 Results presented at the 21st Annual Congress of the European Respiratory Society.
- 26 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Jan 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.